Clinical Trial Search

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Mean Prostate Specific Antigen (PSA) Level — 0.61; 0.70; 0.54 ng/mL

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants

Primary: Percentage of Participants With Total Serum PSA Response — 29; 32; 11; 21 % of responders

Primary: True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy — 13; 7; 6 participants

Primary: Overall Survival

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants

Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline

Primary: Cancer Detection Performance of FACBC PET/CT — 17; 22; 4; 14 Participants

Primary: Composite Time to Disease Progression (cTTP) for Participants Treated With Cixutumumab — 4.9; 3.2 months

Primary: Number of Participants Who Received At Least 1 Infusion of Sipuleucel-T in Men With Metastatic Castrate-resistant Prostate Cancer (CRPC) — 98 participants

Primary: Overall Time to Disease Progression — 10.9; 9.9 Weeks — p=0.719

Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants

Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants

Primary: Number of Participants With Stable, Decreased, or Increased PSA Doubling Times (PSADT) — 7; 2; 17 Participants

Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients

Primary: Percent Probability of Participants With 6-month Progression-free Survival (PFS) — 43.9 percent probability

Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months

Primary: Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months — 10 Participants

Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…

Primary: Change Rate of Prostate-specific Antigen (PSA) < Nadir + 2 ng/mL From First Day of Treatment to 15 Months (Cohort 2) — 100; 100 percentage of participants

Primary: Combined pCR or MRD Rate [Part 1] — 12; 12 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events — 10; 1; 2; 37 Participants

Primary: Metabolic Syndrome — 0; 0 kilograms